Actively Recruiting
Evaluating Safety and Tolerability of LIQ861 Inhalation Powder in Adults With WHO Group 1 Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
Led by Liquidia Technologies, Inc. · Updated on 2026-10-02
20
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of LIQ861 treprostinil inhalation powder in adults aged 18 to 80 years with pulmonary arterial hypertension PAH, WHO Group 1. The study focuses on patients transitioning from selexipag, an oral medication, to inhaled treprostinil. This open-label Phase 4 trial aims to understand how switching treatments affects walking ability, heart strain markers, and patient-reported symptoms. Participants will stop taking selexipag on the first study day and begin using LIQ861 four times daily via a handheld dry powder inhaler. The dose of LIQ861 may be adjusted over time based on how well participants tolerate the medication. They will continue this inhaled treatment for 16 weeks. During the study, participants may also be receiving up to two other stable oral PAH therapies. Throughout the study, participants will be monitored for side effects and serious adverse events from the first day through 30 days after their last dose, which may last up to about 24 weeks in total. Researchers will also assess walking distance and collect blood markers related to heart strain, along with participant symptom reports. Participants will be trained on correct inhaler use and will have regular assessments during the trial.
CONDITIONS
Brief Title
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
Research Team
L
Liquidia Point of Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here